Evidence map›Paper›PMID 27530145›Full record

ArticleScientific reports2016

Recombinant adenovirus of human p66Shc inhibits MCF-7 cell proliferation.

Xiaoshan Yang, Rong Xu, Yajun Lin, Yongzhan Zhen, Jie Wei, Gang Hu, Hongfan Sun

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiaoshan YangTianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Peking Union Medical College &Chinese Academy of Medical Sciences, Tianjin 300192, China.
Rong XuTianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Peking Union Medical College &Chinese Academy of Medical Sciences, Tianjin 300192, China.
Yajun LinThe key Laboratory of Geriatrics, Beijing Hospital &Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730, China.
Yongzhan ZhenDepartment of Histology and Embryology, College of Basic Medical, Hebei United University, Tangshan, 063000, China.
Jie WeiThe key Laboratory of Geriatrics, Beijing Hospital &Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730, China.
Gang HuThe key Laboratory of Geriatrics, Beijing Hospital &Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730, China.
Hongfan SunTianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Peking Union Medical College &Chinese Academy of Medical Sciences, Tianjin 300192, China.
Beijing Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNNorth China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this work was to construct a human recombinant p66Shc adenovirus and to investigate the inhibition of recombinant p66Shc adenovirus on MCF-7 cells. The recombinant adenovirus expression vector was constructed using the Adeno-X Adenoviral System 3. Inhibition of MCF-7 cell proliferation was determined by MTT. Intracellular ROS was measured by DCFH-DA fluorescent probes, and 8-OHdG was detected by ELISA. Cell apoptosis and the cell cycle were assayed by flow cytometry. Western blot were used to observe protein expression. p66Shc expression was upregulated in 4 cell lines after infection. The inhibitory effect of p66Shc recombinant adenovirus on MCF-7 cells was accompanied by enhanced ROS and 8-OHdG. However, no significant differences were observed in the cell apoptosis rate. The ratio of the cell cycle G2/M phase showed a significant increase. Follow-up experiments demonstrated that the expressions of p53, p-p53, cyclin B1 and CDK1 were upregulated with the overexpression of p66Shc. The Adeno-X Adenoviral System 3 can be used to efficiently construct recombinant adenovirus containing p66Shc gene, and the Adeno-X can inhibit the proliferation of MCF-7 cells by inducing cell cycle arrest at the G2/M phase. These results suggested that p66Shc may be a key target for clinical cancer therapy.

Indexed as

Recombination, Genetic8-Hydroxy-2'-DeoxyguanosineAdenoviridaeCell Cycle CheckpointsCell ProliferationDeoxyguanosineHEK293 CellsHeLa CellsHumansHuman Umbilical Vein Endothelial CellsMCF-7 CellsPhosphorylationReactive Oxygen SpeciesSrc Homology 2 Domain-Containing, Transforming Protein 1Tumor Suppressor Protein p53Up-Regulation8-Hydroxy-2'-DeoxyguanosineDeoxyguanosineReactive Oxygen SpeciesSHC1 protein, humanSrc Homology 2 Domain-Containing, Transforming Protein 1TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID27530145
PMCPMC4987618
OpenAlexW2517016056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.